Amneal Announces $272.5m Opioid Settlement Amid Positive Q1 Earnings
The Settlement Gives Out $92.5m In Cash Alongside $180m Of Naloxone Donations
Amneal has joined the ranks of generics manufacturers who had to pay millions to settle legal claims linked to the sector’s alleged role in the US opioid epidemic.
